Trastuzumab exerts its anti-tumor activity via the blockade of constitutive HER2 signaling and the recruitment of FcR expressing immune effector cells responsible for antibody-dependent-cell cytotoxicity (ADCC) [7]. The gene discussed is ERBB2; the disease is neoplasm.